Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07384910

Assessment of GARP Expression in Acute and Chronic Coronary Syndrome

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Atheroma; Heart Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Heart Diseases Myocardial Ischemia Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Plaque, Atherosclerotic Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium

Location contact

Christophe Beauloye, Medical Degree

PRINCIPAL_INVESTIGATOR

Louis Charki, Medical Degree

CONTACT

[email protected]

+3224362014

Louis Charki, Medical Degree

SUB_INVESTIGATOR

Shakeel Kautbally, Medical Degree

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Older than 18 years
  • Able to give informed consent
  • Undergoing coronary angiography.

Exclusion criteria

  • Patients younger than 18 years
  • Unable to give consent
  • Pregnancy
  • Dialysis

Treatment and study plan

Arterial blood sample

Biological

An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.

Primary outcomes

  1. Platelet GARP expression

    Time frame: Throughout the entire study, approximately during 2 years

    The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.

Secondary outcomes

  1. Inflammatory profile

    Time frame: Throughout the entire study, approximately during 2 years

    The inflammatory cytokines (IL-1, IL-6, TNF,...) profile will be determined by multiplex and compared between arms.

Study contacts

Contact information is provided by the study sponsor or research team.

Louis Charki, Medical Degree

CONTACT

[email protected]

+3224362014

Sponsors and collaborators

Lead sponsor

Université Catholique de Louvain

Other

Collaborators

  • Fonds National de la Recherche Scientifique

Registry information

Official study title

Assessment of GARP Expression and Inflammatory Cytokines in Acute and Chronic Coronary Syndrome

Acronym: GARP-CS

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 3, 2026
Registry last updated
Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.